#GlobalExpansion

GNI Group is strengthening its global expansion centered on the US and China, with the acquisition of Gyre Therapeutics scheduled for completion in Q2 2026. The R&D pipeline consists of 23 products, with 990 employees as of the end of December 2025.

From fiscal 2026, RSUs will be granted to approximately 1,800 management leaders, introducing a trust scheme worth 65 billion yen. ESPP is planned for global rollout targeting up to 150,000 employees by fiscal 2027.